Follicular lymphoma is a slow-growing, indolent form of non-Hodgkin lymphoma that primarily affects the lymphatic system. It accounts for 20%-30% of all non-Hodgkin lymphoma (NHL) cases globally. Despite various treatment options, there remains a significant unmet clinical need for more effective therapies, as current options, such as chemotherapy and immunotherapy, may lead to relapse or resistance. The follicular lymphoma pipeline analysis by Expert Market Research focuses on various treatment options for this disease. Emerging follicular lymphoma drugs, including CAR T-cell therapies and bispecific antibodies, show promise in improving patient outcomes and addressing this ongoing medical challenge.
Major companies involved in the follicular lymphoma pipeline drugs market include Novartis Pharmaceuticals, Celgene Corporation, and others.
Leading drugs currently in the pipeline include Tazemetostat, SHR2554, and others.
The high unmet clinical need, the increasing incidence of follicular lymphoma, and advancements in targeted therapies, such as CAR T-cell treatments and bispecific antibodies, are driving significant growth in the follicular lymphoma drug development pipeline.
The Follicular Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into follicular lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for follicular lymphoma. The follicular lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The follicular lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with follicular lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to follicular lymphoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Follicular lymphoma (FL) is a slow-growing, non-Hodgkin lymphoma originating from B-lymphocytes. It occurs when genetic mutations, often involving the BCL2 gene, cause uncontrolled cell division and inhibit apoptosis. This leads to enlarged lymph nodes, fatigue, and weight loss. FL typically develops in lymphoid tissues but can spread to other organs, making early detection essential for effective management.
Follicular lymphoma treatments include chemotherapy, immunotherapy, and targeted therapies to inhibit cancer cell growth. Radiation therapy is effective for localized disease, while stem cell transplantation is an option for aggressive or relapsed cases. Newer treatments, such as CAR-T cell therapy, show promise in enhancing patient outcomes and extending remission periods. In June 2024, the United States Food and Drug Administration granted accelerated approval to Epcoritamab-bysp (Epkinly®) for treating relapsed or refractory follicular lymphoma, following positive results from the EPCORE® NHL-1 trial.
Follicular lymphoma is the most common low-grade non-Hodgkin lymphoma, representing 20%-30% of all non-Hodgkin lymphoma cases. In the United States, follicular lymphoma has an incidence of 6 cases per 100,000 people annually. The United Kingdom reports around 2,300 new cases each year, while in India, follicular lymphoma constitutes approximately 7.2% of non-Hodgkin lymphoma cases.
This section of the report covers the analysis of follicular lymphoma drug candidates based on several segmentations, includ
By Phase
The pipeline report covers 50+ drug analyses based on phase:
By Drug Class
The follicular lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total follicular lymphoma clinical trials, with47.37%, highlighting strong mid-stage development activity. Phase I follows at 41.18%, indicating robust early-stage innovation. Phase III accounts for 10.84%, showing promising advancements nearing regulatory review. Early phase I contributes 0.62%, reflecting exploratory efforts. This balanced pipeline can significantly boost treatment options for follicular lymphoma.
The drug molecule categories covered under the follicular lymphoma pipeline analysis include monoclonal antibodies, small molecules, bispecific antibodies, CAR T-cell therapies, antibody-drug conjugates, and others. The follicular lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for follicular lymphoma. Chimeric antigen receptor (CAR) T-cell therapies are emerging as promising options in the follicular lymphoma treatment pipeline. For instance, lisocabtagene maraleucel (Breyanzi) received FDA accelerated approval in May 2024 for adults with relapsed or refractory follicular lymphoma after two or more systemic therapies. It showed a 95.7% overall response rate in the Phase 2 TRANSCEND-FL trial.
The EMR report for the follicular lymphoma pipeline report covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed follicular lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in follicular lymphoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for follicular lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of follicular lymphoma drug candidates.
Tazemetostat (TAZVERIK), an EZH2 inhibitor developed by Epizyme, Inc., is being evaluated in a Phase 3 trial for relapsed/refractory follicular lymphoma (FL). This study examines its efficacy, safety, and pharmacokinetics when combined with Lenalidomide and Rituximab, aiming to improve progression-free survival in patients with EZH2 mutations or limited treatment options. Tazemetostat is a first-in-class EZH2 methyltransferase , targets EZH2 mutations in follicular lymphoma. It inhibits tumor growth by reversing gene silencing, offering potential therapeutic benefits.
SHR2554 is a selective oral EZH2 inhibitor that disrupts cancer cell growth by targeting H3K27Me3 levels, inducing apoptosis, and inhibiting lymphoma progression, offering promising therapeutic potential. Jiangsu Hengrui Medicine Co., Ltd. is sponsoring a Phase II, single-arm, open-label study to evaluate the efficacy and safety of SHR2554 in patients with relapsed or refractory follicular lymphoma. SHR2554 is an oral inhibitor of EZH2 , a targeted therapy for lymphomas.
AZD0486, sponsored by AstraZeneca, is currently being evaluated in a global Phase III study for previously untreated follicular lymphoma. This bispecific T-cell engager , developed using UniRat technology, targets immune checkpoints. The objective is to assess its efficacy and safety in combination with rituximab, compared to standard immunochemotherapy regimens. AZD0486 is administered intravenously.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Follicular Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for follicular lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into follicular lymphoma collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share